现实AD-验证了早期阿尔茨海默病的现实查方法
Antoine Leuzy1,2,3, Fiona Heeman1,2, Iris Bosch2,3
1Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|September 23, 2024
概括
这项研究验证了血液生物标志物和远程认知测试,用于在瑞典初级保健中早期检测阿尔茨海默病 (AD). 这种方法旨在改善阿兹海默症患者的诊断和预后.
科学领域:
- 神经学 神经学
- 生物标志物 生物标志物
- 医疗保健管理的管理
背景情况:
- 早期诊断阿尔茨海默病 (AD) 对于成功治疗至关重要,但目前的医疗保健系统缺乏广泛查的资源.
- 阿尔茨海默病的临床前阶段是漫长的,需要可扩展和成本有效的早期检测方法.
- 瑞典现有的初级保健机构对阿尔茨海默病生物标志物的获取有限,这阻碍了及时诊断.
研究的目的:
- 为了验证血液基生物标志物和远程认知测试的诊断和预后性能,用于早期发现AD.
- 评估在现有的初级医疗保健基础设施内实施这些新的查方法的可行性.
- 开发一个具体的,个性化的诊断框架,以改善阿尔茨海默病的预后.
主要方法:
- 该REAL AD研究将验证基于血液的生物标志物和远程认知测试.
- 该研究将利用瑞典Västra Götaland地区现有的医疗保健基础设施.
- 重点是对中年个体早期阿尔茨海默病 (AD) 病理学的查.
主要成果:
- 在血液生物标志物和远程认知测试研究队伍中报告了有希望的结果.
- 需要在基于人口的环境中进行验证,以确认这些方法的有效性.
- 现实AD研究旨在提供这一至关重要的验证.
结论:
- 结合基于血液的生物标志物和远程认知测试,为早期AD检测提供了可扩展,具有成本效益的方法.
- 在初级保健机构内验证对于广泛实施至关重要.
- 成功实施可以显著改善阿尔茨海默病的诊断,预后和治疗选择.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.2K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:30Dementia
102
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
102